Outcome of self administered medical abortion pills by patients

Neelam Goyal, Sanjay Kumar Goyal


Background: Study of complication rate in patients presenting in Gynaec OPD after consuming self-prescribed medical abortion pills for unwanted pregnancies. Unchecked sale of Mifepristone and Misoprostol from pharmacies without prescription is giving rise to new emergencies in Gyn and Obs OPDs, which need to be urgently looked after by the authorities and public awareness regarding it’s abuse.

Methods: 200 patients of reproductive age group from 17 yrs to 42 yrs over a period of 2 years from Apr 2014-Apr. 2016, who presented after consuming abortion pills, themselves, purchased over the counter from various pharmacies. Presenting complaints and complications were recorded and procedures required were analysed.

Results: Significant percentage of patients landing into severe anemia, sepsis, incomplete abortions. Two patients required surgery for ruptured ectopic and one diagnosed as hydatiform mole, 3 pregnancies continued to second trimester.

Conclusions: The high rate of medical complications occurring due to absence of medical surveillance of such patients and due to lack of protocol of Gynaec examination and ultrasound, it is highly recommended to have a better control over the unabated sale of these drugs at the pharmacies.


Medical abortion, Abortion pills, Unwanted pregnancies

Full Text:



Creinin MD. Medical abortion regimens: historical context and overview. Am J Obstet Gynecol 2000;183:(2):S3-S2.

Jones RK, Henshaw SK. Mifepristone for early medical abortion: Experiences in France, Great Britain and Sweden. Perspect Sex Reprod Health. 2002;34:154-61.

Grimes DA. Risks of mifepristone abortion in context. Contraception. 2005;71:161.

Atrash HK, Hogue CJ. The effect of pregnancy termination on future reproduction. Baillieres Clin Obstet Gynaecol. 1990;4:391-405.

Frank PI, McNamee R, Hannaford PC, Kay CR, Hirsch S. The effect of induced abortion on subsequent pregnancy outcome. Br J Obstet Gynaecol. 1991;98:1015-24.

Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol. 2000;183:(2):S65-75.

Current trends ectopic pregnancy-United States, 1990-1992. Atlanta: Centers for Disease Control and Prevention, January 1995.

Bouyer J, Coste J, Shojaei T. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case-control, population-based study in France. Am J Epidemiol. 2003;157:185-94.

Knudsen UB. First trimester abortion with mifepristone and vaginal misoprostol. Contraception 2001;63:247-50.

Christensen K, Schmidt MM, Vaeth M, Olsen J. Absence of an environmental effect on the recurrence of facial-cleft defects. N Engl J Med. 1995;333:161-4.

International Classification of Diseases (ICD) online. Geneva: World Health Organization. (Accessed July 20, 2007, at

Olsen J, Melbye M, Olsen SF. The Danish National Birth Cohort-its background, structure and aim. Scand J Public Health. 2001;29:300-7.

World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation. Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost: a randomized controlled trial. Acta Obstet Gynecol Scand 2001;80:447-51.

Chen A, Yuan W, Meirik O. Mifepristone-induced early abortion and outcome of subsequent wanted pregnancy. Am J Epidemiol. 2004;160:110-7.

Chow WH, Daling JR, Cates W, Greenberg RS. Epidemiology of ectopic pregnancy. Epidemiol Rev. 1987;9:70-94.